Edaravone: A New Treatment for ALS

Toru Yamashita, Koji Abe

Research output: Contribution to journalArticlepeer-review


In 1993, a mutation in the superoxyde dismutase gene, SOD1, was found causative for familial ALS, suggesting that free radical-related injury may be involved in ALS pathogenesis. Therefore, clinical trials were conducted with ALS patients using a free radical scavenger, edaravone, which was already approved for acute phase treatment of cerebral infarction in Japan. Because edaravone showed a therapeutic effect in suppressing the progression of ALS symptoms, it was approved as a new therapeutic agent in Japan, in June, 2015. In this article, we discuss the recent progress of basic and clinical research for the development of new ALS treatments.

Original languageEnglish
Pages (from-to)1245-1251
Number of pages7
JournalBrain and nerve = Shinkei kenkyu no shinpo
Issue number11
Publication statusPublished - Nov 1 2019

ASJC Scopus subject areas

  • Clinical Neurology


Dive into the research topics of 'Edaravone: A New Treatment for ALS'. Together they form a unique fingerprint.

Cite this